Multiple Acquired Resistance Mutations of the ALK Tyrosine Kinase Domain after Sequential Use of ALK Inhibitors

J Thorac Oncol. 2017 May;12(5):e49-e51. doi: 10.1016/j.jtho.2017.01.009.

Authors

Hsin-Yi Wang¹, Chao-Chi Ho², Jin-Yuan Shih³

Affiliations

¹ Department of Internal Medicine, National Taiwan University Hospital, Yunlin Branch, Yun-Lin, Republic of China.
² Department of Internal Medicine, National Taiwan University Hospital, Taipei, Republic of China; College of Medicine, National Taiwan University, Taipei, Republic of China.
³ Department of Internal Medicine, National Taiwan University Hospital, Taipei, Republic of China; College of Medicine, National Taiwan University, Taipei, Republic of China. Electronic address: shihjy@ntu.edu.tw.

PMID: 28434515
DOI: 10.1016/j.jtho.2017.01.009

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Anaplastic Lymphoma Kinase
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / enzymology
Carcinoma, Non-Small-Cell Lung / genetics
Carcinoma, Non-Small-Cell Lung / pathology
Drug Resistance, Neoplasm
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / enzymology
Lung Neoplasms / genetics
Lung Neoplasms / pathology
Male
Middle Aged
Mutation*
Protein Kinase Inhibitors / therapeutic use*
Receptor Protein-Tyrosine Kinases / antagonists & inhibitors*
Receptor Protein-Tyrosine Kinases / genetics*

Substances

Protein Kinase Inhibitors
ALK protein, human
Anaplastic Lymphoma Kinase
Receptor Protein-Tyrosine Kinases